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1 Introduction and Study Goals 
1.1 Background 
 Wang et al. have characterized a hepatic progenitor cell population 
isolated from uninjured adult mouse liver that phenotypically differentiates into 
both hepatocytic and biliary cell populations [50]. It was observed in subsequent 
transplant experiments that direct injection of this cell population (into the spleen 
or liver) is associated with a high incidence of pulmonary embolism rather than 
cellular engraftment. This suggests that despite direct tissue injection the cells 
rapidly enter the vasculature of the recipient and subsequently embed within the 
pulmonary vascular system (Data not shown). These initial findings are critical in 
understanding the potential utility of the progenitor cell population in clinical 
therapies. Unfortunately the efficacy of cellular transplantation with somatic-
derived progenitor cell populations (e.g. hepatic progenitor cells) is limited by the 
inherent requirement for the cell population to exist in an environment that 
supports cell viability and function [59-61].  
 Based on the previously described cell transplant experiments it was 
hypothesized that creating a cellular niche is a critical step to support progenitor 
cell proliferation and differentiation. The goal of the dissertation research was to 
develop a three-dimensional environment for the hepatic progenitor cells that 
would optimize their proliferative potential and their ability to differentiate.
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 It was theorized that the creation of an ideal three dimensional model 
where the cells can be cultured at higher densities (due to the physical 
characteristics and volume of the biohybrids) would circumvent the physical 
constraints of standard two-dimensional culture systems. In addition, utilizing 
these methods for creating a neo-microenvironment for the progenitor cells 
allows further ex-vivo manipulation to optimize cell proliferation, function and the 
potential to deliver the cells in-vivo.  
1.2 Project Goals 
The main goals of this dissertation research were as follows: 
 
1. To create a milieu wherein hepatic progenitor cells (HPCs) can be 
provided an ex-vivo 3-dimensional culture condition to proliferate and 
differentiate into mature phenotype. 
2. To analyze the effect of such biohybrids on HPCs including their bi-
potency and sustenance of function. 
3. To establish a procedure for transplantation of HPCs integrated on 
resorbable biohybrids. 
4. To provide HPCs with an environment to protect them from the recipient’s 
immune system. 
5. To develop systems for cellular encapsulation to facilitate cell transplant. 
6. To translate experience gained with encapsulation techniques to the 
MEMS/microfluidics platform for purposes of cell delivery and analysis of 
drug/cytokine metabolites. 
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1.3 Manuscript Preparation 
The findings of this study were presented at recognized scientific 
conferences and one manuscript has been previously published in the “Tissue 
Engineering” journal. Additional manuscripts are currently being prepared for 
submission. The list of presentations and publications is listed below. 
 
• Chandrasekaran P, Neill ATO, Walker GM, Gerber DA - “Microfluidic Approach 
to Collagen Microencapsulation” – Article in Preparation. 
 
• Chandrasekaran P, Neill ATO, Walker GM, Gerber DA - “Microfluidic Culture of 
Hepatic Progenitor Cells in Collagen Microspheres” – Article in Preparation 
 
• Chandrasekaran P, Neill ATO, Walker GM, Gerber DA - “Microfluidic System 
for Collagen Encapsulation of Cells” – Biophysical Society Meeting, Baltimore, 
MD – March 2007. 
 
• Chandrasekaran P, Seagle C, Rice L, Macdonald J, Gerber DA - “Functional 
analysis of encapsulated hepatic progenitor cells.” – Tissue Eng. 2006 Jul; 
12(7):2001-8. 
 
• Wright N, Rice LL, Walkup M, Chandrasekaran P, Gerber DA - “Enrichment of 
a Bipotent Hepatic Progenitor Cell from Naïve Adult Liver Tissue” – (Submitted 
for peer review). 
 
• Chandrasekaran P, Walkup M, Wright N, Seagle C, Macdonald J, Gerber DA - 
“Novel technique for co-culture of Sca-1+ hepatic progenitor cells and hepatic 
non-parenchymal cells.” – North Carolina Tissue Engineering and Regenerative 
Medicine Meeting, Aug 2006. 
 
• Chandrasekaran P., Wang J., Sadiq T., Gerber DA - “Development of a Bio-
hybrid liver using 3D Biodegradable Scaffolds and Hepatic Progenitor Cells”-
North Carolina Tissue Engineering Interest Group Meeting, Research Triangle 
Park, NC, June 2003. 
 
 
 
 
 
 
 
 
 
 
2 Literature Review 
2.1 Tissue Engineering for Organ Replacement 
Tissue engineering is the science of using living cells to restore and 
rebuild tissues and organs. Engineered tissues could greatly reduce the need for 
organ replacement and could also help in the development of new drugs [1]. Age 
related organ degeneration is another reason for the increased demand for 
engineered tissues. Unlike some pathological conditions from which the body can 
recover, organ degeneration can be permanent requiring immediate whole organ 
transplants. Due to the long waiting period for these procedures, engineered 
tissues are being used to maintain temporary function in the diseased organs 
until a suitable replacement can be found. Examples of such maladies are end 
stage renal or liver disease and macular degeneration. 
The conventional approaches for tissue or organ replacement [2] are: 
Autografts 
This is the process referred to as “creating a wound to fix a wound”. 
Tissue from one location in the patient is harvested and transplanted to another 
location. The main advantage of this procedure is it produces almost no immune 
response since the tissue is not recognized as foreign. The main disadvantage is 
risk of pain and infection at the tissue harvest site. An example of an autograft is 
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a coronary bypass procedure where veins are harvested from the patient’s leg 
and used to replace blocked arteries in the heart. 
Allografts 
These are organs or tissue obtained from an allogeneic donor and then 
transplanted into a recipient. The donor may be dead or alive depending on the 
organ donated. The challenge with allografts is that the patient’s immune system 
will recognize the tissue as “foreign” and initiate an immune response to reject 
the tissue. Tremendous advances in drugs that prevent or minimize rejection 
(immunosuppressive agents) have been developed so that the problem of 
rejection is currently more manageable. Unfortunately, the shortage of organ 
donors remains a significant limitation in transplantation.  
Artificial Materials and Devices 
The field of Biomedical Engineering has brought together the fields of 
medicine and engineering which has enabled the creation of devices and 
materials that mimic biological systems [3]. These devices and materials can be 
used to augment or even replicate functions performed by natural organs. These 
devices do not behave physiologically like true organs or tissues. Thus, these 
devices are best suited as temporary therapies until a donor organ becomes 
available. 
 Other available technologies include obtaining tissues and organs by 
cloning and gene therapies. While these two have received much publicity, many 
problems will need to be overcome before they become clinically available. 
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2.2 Stem Cells in Tissue Engineering 
One important criterion in tissue engineering is the choice of cell type. The 
cells are expected to take up residence in the implant material, proliferate, form 
colonies and populate the tissue. It is thus important that we choose a cell type 
that has good proliferation characteristics. Typical tissue engineering applications 
have employed mature cell populations to populate tissue constructs with limited 
success. This is because mature cell types have low proliferative capabilities. 
Proliferative potential however, is not the only decisive factor in the choice 
of cell type. The grafted cell should also be capable of responding to external 
stimuli and respond by differentiating into a mature cell type which forms the bulk 
of the tissue/organ.  
The availability and use of stem cells has revolutionized the field of tissue 
engineering [4]. Stem cells were initially thought to exist only in the bone marrow 
but recent studies have proven that many tissues in the body have their own 
stem cell compartment. The field of embryonic stem cell research is also gaining 
importance. 
Stem cells can be broadly classified into two major types:  
Embryonic Stem Cells 
These cells are obtained from very early stages of the embryo called the 
blastocyst. The inside of the blastocyst called the inner cell mass is harvested 
and cultured to obtain embryonic stem cells [5]. 
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Figure 2-1: Schematic for isolation of Embryonic Stem Cells. 
(Image Source: http://stemcells.nih.gov ) 
 
Since embryonic stem cells are undifferentiated, they can differentiate to 
form any cell in the body. This totipotent characteristic of these cells makes them 
important in regenerative medicine. They also possess excellent proliferation 
characteristics as they are at the beginning of their differentiation cycle. However, 
since these cells are obtained from the embryo, there are ethical issues involved 
with their usage. 
  
Adult Stem Cells 
Adult or somatic stem cells are isolated from mature tissues and are 
believed to be involved in normal regeneration of the tissue upon injury or 
disease. These cells are “undifferentiated” and are found scattered within the 
tissue or organ. The cells are said to be “committed” and can only form the type 
of tissue from which they are harvested. They form a basis for the tissue or 
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organ’s response to injury. Upon injury or cell loss, they can divide and 
differentiate into the major cell types of that tissue or organ. As a result, they can 
be potentially used to treat tissue loss. 
These cells do not pose ethical and moral issues as they are isolated from 
adult tissue. Adult stem cell research has gained immense importance because 
of the huge controversy surrounding embryonic stem cell research. Recent 
research has also shown that some adult stem cells are capable of trans-
differentiation to cells of other tissue types. 
2.3 Adult Stem Cell Research – Past and Present 
In the 1960’s it was found that bone marrow contains two kinds of stem 
cells, the hematopoietic stem cells and the bone marrow stromal cells. The 
hematopoietic stem cells are known to form all the blood cell types in the body. 
The stromal cells differentiate to form bone, cartilage, fat and other fibrous 
connective tissue. At the same time, scientists also discovered that the rat brain 
has resident cells that can differentiate to form the major cell types of the brain 
(astrocytes, oligodentrocytes and the neurons). Scientists all across the world 
have since then discovered stem cells in all major organs of the body. Adult stem 
cells compartments have been discovered in the brain, heart, bone marrow, 
blood vessels, muscle and liver [5]. 
The problem with adult stem cells is that they constitute a very small 
portion of the cell mass. They remain dormant until they are activated by 
conditions such as disease or physical injury. Scientists are now working on 
mechanisms to isolate, culture and expand this stem cell population ex-vivo with 
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the aim of transplanting these cells into injured tissue to enable recovery. The 
issue of identifying and isolating these stem cells from the myriad of cells in every 
tissue/organ has perplexed researchers. 
Research is ongoing to develop methods to successfully identify these 
cells from the heterogeneous cell population in the tissue. The most popular 
method to isolate these stem cells has been to select a molecular marker that is 
expressed on the cell of interest and use techniques like flow cytometry to sort 
the cell population that is positive for that marker. Research is also underway to 
find molecular markers globally expressed on such adult stem cells. There is no 
agreement on the choice of cell type among researchers yet. 
Graft rejection is a difficult problem in transplant medicine that can only be 
circumvented with immunosuppressive drugs. Adult stem cells can be isolated 
from a patient's own cells, expanded and preserved and then transplanted back 
into the patient. Use of adult stem cells would mean that the cells would not be 
rejected by the immune system. This represents a significant advantage as the 
difference between donor demand and supply widens. 
The discovery of adult stem cells in many tissues has created 
opportunities for researchers to find answers that have previously eluded them. 
Since stem cells have the capacity to self renew they can create genetically 
identical copies of themselves called clones. Research is ongoing to produce 
adult stem cell lines that are “undifferentiated” and can be coaxed with external 
stimuli to differentiate into a mature cell type of that tissue when needed. This 
has a huge demand in the field of cell transplant therapy where the clones can be 
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injected into the damaged tissue, engraft, differentiate and replace the tissue’s 
lost cell mass. 
2.4 Biohybrids for Tissue Regeneration 
The discipline of tissue engineering has gained importance in recent 
years. To engineer living tissues in vitro, cultured cells must be coaxed to grow 
on bioactive degradable scaffolds that guide their differentiation and assembly 
into three-dimensional (3D) tissues [6]. These bio-hybrids are then cultured and 
transplanted to induce the growth of new tissue. The goal is to induce cell 
attachment, proliferation and differentiation into normal healthy tissue as the bio-
hybrid construct degrades. Skin and bone replacement have been the best 
success stories so far in tissue engineering. Many issues need to be resolved in 
order to enable creation of more complex tissues like heart and liver. 
2.5 Micro-Encapsulation for Tissue Regeneration 
The basic principle of micro-encapsulation is to provide the encapsulated 
cells with a protective microenvironment. The cells are protected from external 
insults like shear and macrophages (upon transplantation). Lim et al. 
encapsulated Islets of Langerhans [7] using a protocol first developed by Chang 
in 1964 [8].  
Encapsulation techniques have been used for the treatment of Parkinson’s 
disease [9], hepatocytes [10] and hypoparathyroidism [11]. Since encapsulation 
is not cell type restrictive, it has also been used to encapsulate genetically 
modified cells and even hormones [12, 13]. The most published application of 
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this method to date has been encapsulation of Islets from the pancreas for 
treatment of diabetes [14-16]. 
2.6 The Liver 
2.6.1 Liver Structure 
The liver is the largest internal organ in the human body [17] and an 
average human liver weighs about 1-2.5 kilograms. The liver is located below the 
diaphragm on the right upper side of the abdomen. It has a dual blood supply of 
which 80% is nutrient-rich blood from the portal vein arising from the stomach, 
intestines and spleen and 20% is oxygen-rich blood from the hepatic artery. At a 
microscopic level, the liver is made up of individual units called lobules. Each 
lobule is surrounded by four to five portal triads and has a central terminal 
hepatic venule. Hepatocytes are the major cell type in the liver. They are 
arranged in plates that branch out from the portal triads toward the central veins. 
The bile canaliculus is found on the contact surface of adjacent liver cells. Bile is 
produced in these canaliculi and drains into the duodenum through ductules, 
interlobular bile ducts and then larger hepatic ducts.  
Sinusoidal lining cells are another important cell group consisting of 
endothelial cells, Kupffer's cells, fat-storing cells and pit cells. The hepatic 
endothelial cells lack a basement membrane unlike the vascular endothelium 
found everywhere else in the body. They contain numerous fenestrae that enable 
hepatocytes to access nutrients and macromolecules in the blood plasma. The 
Kupffer’s cells constitute the liver macrophage compartment. The major functions 
of this cell type are phagocytosis of foreign objects, removal of harmful toxins 
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and the release of agents that modulate the tissue’s immune response. Fat-
storing cells (Ito cells) are the storehouse for Vitamin A. They are converted into 
fibroblasts upon liver injury, causing hepatic fibrosis. Pit cells, the least common 
sinusoidal cell type, are lymphocytes, which function as natural killer cells (NK 
cells). 
Another cell type that is normally in the quiescent state is the hepatic 
stellate cell. These cells are activated during liver cirrhosis when they 
overproduce certain proteins, such as type I collagen.  The extra-cellular matrix 
of the liver includes its reticulin framework and several molecular forms of 
collagen, laminin, fibronectin and other extra-cellular glycoproteins. 
2.6.2 Liver Functions 
The liver plays an important role in the body’s metabolic process [18] and 
also fulfils functions such as detoxification, glycogen storage and synthesis of 
coagulation factors in the plasma. A majority of the liver functions are carried out 
by the liver cells also called hepatocytes. 
Some of the important functions of the liver are: 
• Secretion of bile 
• Metabolism of carbohydrates (Includes gluconeogenesis and glycogen 
synthesis) 
• Lipid metabolism (synthesis of cholesterol) 
• Breakdown of hormones (insulin) 
• Production of blood coagulation factors (fibrinogen etc.) 
• Detoxification of blood and neutralization of drugs 
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• Conversion of ammonia to urea 
• Other functions include storage of glycogen, Vit.B12 etc. 
2.6.3 Rationale behind Cellular Encapsulation 
 Clinical advances in surgical technique and immunosuppression have 
made liver transplantation the primary clinical option for patients with end-stage 
liver disease [41, 42]. Despite optimized use of donor livers through split liver 
transplantation and living-donor liver transplantation; organ needs do not meet 
the increased demand by patients diagnosed with advanced liver disease [43, 
44]. 
 Several cell-based therapies for liver disease have been proposed 
because of this severe donor shortage (e.g. extracorporeal bio-artificial liver 
devices, cell transplantation, and tissue-engineered liver constructs) [45, 46]. 
These therapies require an adequate cell supply with stability of liver-specific 
functions. Although extracorporeal cell-based support devices have been studied 
in clinical trials, the efficacy of engineered cell therapies in the management of 
liver disease requires further improvements to incorporate approaches for 
maximizing hepatocyte function. To apply such strategies, we must integrate 
principles from liver biology as well as the clinical experience for supporting 
patients with liver failure. 
 Successful cellular therapies must therefore integrate individual liver-
derived cell populations into a microenvironment that supports their potential 
expansion and maintains liver-specific functions. Unfortunately, the full gamut of 
cellular functions required to replace the liver and affect clinical outcomes has yet 
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to be fully determined. Mature hepatocytes have been previously used in cell 
transplantation but have had minimal success due to their limited engraftment, 
sensitivity to ischemia and minimal proliferative ability [22, 47-49]. 
 Wang et al. characterized a hepatic progenitor cell population isolated 
from uninjured adult liver that phenotypically differentiates into both hepatocytic 
and biliary cell populations [50]. It is theorized that since hepatic progenitor cells 
have proliferative potential and the ability to differentiate to mature cells, they 
may be better suited for transplantation than mature hepatocytes [51-58]. 
 Numerous challenges still exist with tissue-derived (or somatic-derived) 
progenitor cell populations like this hepatic progenitor cell. It is challenging to 
isolate these cells as they are typically quiescent in their in situ state and the 
requisite signals (either through paracrine signaling from other cells or the 
microenvironment) are frequently unknown. 
 
 
 
 
 
 
 
 
 
 
 3 Hepatic Progenitor Cells on Collagen Biohybrids 
3.1 Introduction 
Tissue engineering techniques to repair or replace failing organs have 
generated great interest due to the shortage of donor organs [68]. These 
techniques typically involve culturing specific cells from the tissue to be replaced 
with support architecture like a porous sponge or scaffold and transplanting them 
to replace the failing organ or to provide sustenance till a replacement organ can 
be found. 
There are typically two approaches to tissue engineering: 
1. A cell biology approach where culture conditions are tweaked so as to 
coax cells to grow and flourish in a 3-dimensional environment. This 
approach usually requires detailed understanding of the biology and 
pathophysiology of the organ being replaced. This approach requires 
knowledge of the different cell types in the organ, their proliferative and 
differentiative abilities and also control over conditions that can induce or 
inhibit such growth. This includes cells mixing cells with different media 
components, cytokines and growth factors.  
The other major area of interest involves creation of co-culture 
systems. Here the proliferation/differentiation cascade of the cell of 
interest is triggered by culturing it in close proximity with another cell type 
 16 
normally found in that organ and permitting signaling between them. This 
signaling could be either by physical contact or by soluble chemical 
signals in a separated co-culture system. The reasoning behind this 
method is that cells in the tissue are never in isolation. They always are in 
contact with other native cell types and there is definite evidence that 
communication between different cells in the organ/tissue is a critical 
feature. Because of this, an optimal tissue engineered organ cannot be 
made using a single cell type but should include the different cells that 
inhabit that organ. 
2. A matrix biology approach where the extracellular matrix is assumed to 
play the most important role in regulating cellular proliferation and 
differentiation. This involves combining novel biomaterials with cells or 
using naturally occurring matrices as tissue replacements. The former 
approach involves adjusting the matrix material to provide the most 
suitable environment for the cell of choice. The latter approach is done in 
engineering tissues like skin, tendon and bone. In these cases, it may not 
be even necessary to include cells in the engineered tissue. The 
biomaterial is expected to integrate into the recipient as their cells grow 
into the implant. One example of such a natural matrix is the small 
intestine submucosa (SIS) that is currently being used as a replacement of 
skin and even tendon. 
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3.2 Tissue Engineering of the Liver – A Historic Perspective 
A successful tissue engineered liver has been the Holy Grail of the field of 
tissue engineering. There are a multitude of reasons that stimulate interest in 
engineering liver tissue and an equivalent number why it has been unsuccessful 
thus far. As explained in detail in an earlier section, the liver is an extremely 
complex organ containing its own stem cell compartment, multiple differentiated 
cell types performing various metabolic functions, and numerous extracellular 
matrix components all performing synergistically. Engineering the liver is tricky 
because of its physical complexity, multifunctionality and the vitality of its function 
for survival. Also troublesome is the fact that differentiated liver cells 
(hepatocytes) lose their function when cultured in-vitro. 
Numerous approaches have been published in the literature for 3-
dimensional culture of liver cells that are directed towards studying the 
physiology, pharmacology and tissue engineering of the liver. They range in 
complexity from culture on collagen coated polystyrene plates [69] to 
microfabricated perfusion chambers [70]. Hepatocytes have also been cultured 
on a plethora of biocompatible materials with a 3-dimensional porous architecture 
including synthetic materials like PLA/PLGA and natural matrices like collagen, 
alginate [71] and hyaluronan and blends of natural and synthetic matrices [72]. 
The majority of the synthetic matrices used in these studies are those approved 
by the FDA for use as suture material. 
The other approach that generated great interest in the 1990s was the 
construction of Bio-Artificial Livers (BAL). A typical BAL design involves 
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inoculating a bioreactor with either primary hepatocytes or immortalized cell lines 
and supplement hepatic function in a patient by processing their blood or plasma 
through the cultured cells [73].  
The majority of the bioreactor designs differ only in two aspects: the 
variation of extracellular matrix design and the cell source. Initial bioreactor/BAL 
designs [74, 75] did not posses a special culture chamber/matrix. They consisted 
of a perfused suspension of hepatocytes immobilized in a bioreactor chamber. 
Later modifications included cell carriers [76], natural matrix substrates 
like collagen [77] and other advanced culture techniques like microencapsulation, 
porous scaffolds, cell-matrix sandwiches and co-cultures of different cell types 
[78,79]. The cells used in BAL systems have traditionally been porcine mature 
hepatocytes due to the shortage of donor organs to obtain human hepatocytes. 
A reliable source of differentiated hepatocytes is required to inoculate the BALs 
on demand as bioreactors primarily function as emergency liver supplements, it 
is required to have. This requires culturing hepatic cells in-vitro and when needed 
induce differentiation into mature hepatocytes. 
 The discovery of a stem cell compartment in the liver has revolutionized 
in-vitro culture of hepatic cells. These include oval cells [80], small hepatocytes 
[72, 73] and hepatic progenitor cells [50]. It is now possible to culture the 
committed undifferentiated cells on 3-dimensional matrices in-vitro and cause 
differentiation using chemical inducers when a BAL is necessary. 
 The lack of a robust BAL design has led researchers to look for other 
potential therapies for liver failure. These include delivery of hepatic cells by 
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direct injection, encapsulating them on 3-dimensional biohybrids or in 
microcapsules.  
3.3 Materials and Methods 
3.3.1 Mice 
C57BL/6 mice were purchased from the Jackson Laboratory (Bar Harbor, 
ME). All animals were maintained on a rodent chow under a constant day/night 
cycle. Six to eight week old mice were used in all experiments. A “GFP tagged” 
mouse model was used for purposes of visualization of cells on the scaffold. 
 All care and use of animals was approved by the Institutional Animal Care 
and Use Committee at the University of North Carolina at Chapel Hill in 
accordance with the principles and procedures outlined in the National Institutes 
of Health Guide for the Care and Use of Laboratory Animals. 
3.3.2 Hepatic Progenitor Cell Isolation 
 Liver cells were isolated using a modification of the two-stage liver 
perfusion technique described by Seglen [62]. The hepatic progenitor cells (HPC) 
were separated from mature hepatocytes using gravity separation and 
centrifugation. Cellular analysis by phase contrast, fluorescent and confocal 
microscopy demonstrated that the hepatic progenitors formed ex vivo colonies 
with a morphological appearance similar to committed hepatocytic progenitors 
isolated from embryonic mice and rats. The protocol was slightly modified from 
the isolation and characterization of HPCs previously established [50]. All initial 
isolation steps were performed on ice to keep the cells metabolically dormant. 
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3.3.3 Collagen Scaffold Preparation 
 BD™ 3D collagen composite scaffolds were sectioned into two pieces with 
a thickness of about 3-5 mm to achieve an open architecture for cellular 
ingrowth. The pieces were then soaked in 70% ethanol for a few hours and air 
dried overnight in a laminar flow hood under ultraviolet light. The sterile scaffolds 
were transferred into 96 well pates for cell culture. 
3.3.4 Cell Loading 
Both HPCs and mature hepatocytes were separately loaded at a 
concentration of about 4x105 cells per scaffold by slowly pipetting the cells 
suspended in growth medium over the scaffold in the 96 well plates.  
After cell-loading the plates were kept on a rocker to aid uniform diffusion 
of nutrients through the scaffold. As a control HPCs were also cultured on 35 mm 
plates with a collagen I coating.  
 The cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
plus 10% fetal bovine serum (FBS), 20mM hepes, 10mM nicotinamide, 1 mM 
ascorbic acid 2-phosphate, 1 µM dexamethasone, 0.5 mg/L ITS (insulin-
transferrin-selenium) solution, 30 mg/L proline, 100 mg/L antibiotic solution, and 
10 ng/ml epidermal growth factor (EGF). 
 The plates were kept in a 5% CO2/95% room air incubator at 37°C. The 
medium was replaced after 1 hour of loading to remove unattached cells and 
subsequently replaced at regular time intervals (3-4 days). The supernatant was 
collected and frozen at each time point for analysis. 
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3.3.5 Light Microscopy 
 The GFP+ cells were visualized with a Zeiss Axiovert 100 inverted 
fluorescence microscope at regular time intervals to ascertain lack of 
contamination and to study cell distribution within the scaffolds and colony 
formation. Care was taken to check for absence of any reading on the red 
(Rhodamine) channel as hepatocytes are notorious for auto-fluorescence. 
3.3.6 Colorimetric Assays for Cellular Proliferation 
As a supplemental test for cellular proliferation and differentiation, urea 
and protein synthesis by the HPCs were analyzed in the media at specific time 
points in culture (1, 4, 7, 10 etc.). These assays were performed according to the 
manufacturer’s protocol using commercially available test kits (Sigma-Aldrich 
Corp.). 
3.3.7 Transplantation of collagen biohybrids 
The collagen biohybrids loaded with GFP+ HPCs were transplanted into 
wild type C57BL/6 mice initially to analyze the effect of the in-vivo environment 
on the cells in the biohybrid. The host mice were sacrificed 1 week post 
transplant to isolate transplant biohybrids. 
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3.4 Results 
3.4.1 Microscopy 
Figure 3-1 shows a SEM image of the BD collagen composite scaffold. 
The image depicts the highly porous nature of the scaffold and even though the 
outer surface appears slightly closed, sectioning it into two presents an open 
architecture for cell penetration into the scaffold center. 
Figure 3-2 is a overlay (fluorescence + transmission) image of mature 
hepatocytes and Figure 3-3 shows fluorescent micrographs of HPCs cultured on 
the BD™ collagen composite scaffold at specific time points in culture. Viable 
cells (HPCs and mature hepatocytes) were found to be uniformly distributed 
through the lumen of the scaffold and are viable even at day 28 in culture. The 
rhodamine channel registered no auto-fluorescence from either the scaffold 
material or the cells. 
 
Figure 3-1: Scanning Electron Micrograph of the BD™ collagen composite scaffold 
showing a closed pore structure on the exterior. 
 Source: B-D Biosciences Catalog 
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Figure 3-2: BD™ collagen composite scaffold loaded with GFP+ mature hepatocytes 
Day 4 (i); Day 21 (ii); Day 28 (iii) in culture. Mag: 10x 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3: Fluorescent micrographs of GFP+ HPCs cultured on the BD™ 3D 
collagen composite scaffold. 
 Day 1 (i), Day 7 (ii), Day 21(iii) and Day 28 (iv). Mag: 10X 
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3.4.2 Colorimetric Assays for Hepatic Function 
The cells’ ability to undergo urea-nitrogen and protein synthesis was 
studied in order to analyze hepatocellular function of the HPCs cultured on the 
collagen scaffolds. Figure 3-4 shows the protein and urea synthesis by HPCs 
cultured on the collagen scaffolds.  
These assays were evaluated at select time points during 2 weeks of 
culture and demonstrate persistence of urea metabolism and protein synthesis 
during that time. The data from both the urea-nitrogen and protein synthesis 
assays were normalized for number of cells loaded per scaffold. 
3.4.3 Transplantation of HPCs on Collagen Biohybrids 
To analyze effect of transplantation on the HPCs, recipient mice were 
sacrificed one week post-transplant. However, the scaffolds could not be found in 
the test site. This shows that the scaffolds cannot be used “out of the box” as a 
transplant vehicle and need to undergo further treatment to increase their 
longevity in-vivo. 
This can be accomplished by treating the collagen scaffolds with 
glutaraldehyde but the toxic effects on the cells need to be evaluated. The other 
alternative is to use natural materials like genipin that has excellent crosslinking 
properties and have been proven to biocompatible when used in combination 
with other polymeric materials (73). 
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Figure 3-4: Total Protein (a) and Urea-Nitrogen (b) synthesis by the HPCs on 
the BD™ Collagen composite scaffold. 
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3.5 Conclusions and Future Work 
Collagen has long been the favored material for building biohybrids for 
purposes of tissue engineering because of its abundance in all tissues and also 
due to its great material properties and biocompatibility. The ability to manipulate 
and mold collagen into desired shapes also leads to its popularity as a tissue 
engineering substrate. 
The BD™ collagen composite scaffold is a natural scaffold manufactured 
from a proprietary mixture of collagens that are derived from bovine hide. Overall, 
this material exhibits collagen fibrillar architecture, which is representative of the 
structure of collagen within the interstitial matrix. 
 From the results, it is evident that cells undergo proliferation and colony 
formation on this substrate. The drop in urea and protein synthesis after Day 10 
in culture is cause for worry. This loss in hepatic function is indicative of two 
possible events: 
(a) De-differentiation of the hepatic progenitor cells into non-committed cells or 
(b) Proliferation of non-parenchymal cells like fibroblasts, stellate cells etc. in the 
isolation matrix that do not express hepatic markers combined with the death of 
the bi-potential progenitor cells. 
 These results suggest a need for a further purified progenitor cell 
population that does not have the mature hepatocyte or non-parenchymal cell 
constituents. Experiments are ongoing to purify the hepatic progenitor cell 
population using a magnetic separation process using the antibody Sca-1 (Stem 
Cell Antibody). 
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 The transplantation study reveals the necessity to crosslink the collagen 
matrix, usage of other natural matrices that have demonstrated better longevity 
when used in-vivo or the usage of other strategies for hepatic therapy or cell 
delivery like encapsulation in matrices like calcium alginate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 Alginate Micro-spheres for Hepatic Therapy 
4.1 Introduction and Literature Review 
 The concept of alginate encapsulation has been well described for several 
decades, but has typically involved encapsulation of mature, differentiated cell 
populations (e.g. islets, mature hepatocytes or cell lines) [19-21]. Alginate is an 
excellent encapsulation substrate because it is a hydrogel (preparation entirely 
aqueous), and it has no detectable adverse effects on cells during preparation or 
post-cast. 
 Alginate maintains its material properties for long periods of time in culture 
[22-33]. The porous properties of sodium alginate also make it an ideal choice for 
cellular encapsulation. Analysis of calcium alginate gels demonstrated a wide 
range of pore size in the gels. This typically fosters the secretion of large 
molecules and growth factors both into and out of the alginate bead. 
Encapsulating the cells with alginate protects them from physical insults that will 
occur during direct injection of these cells. These insults include decreased cell 
viability from shear during injection and minimizing direct cell contact with 
phagocytic cells of the host upon transplant [37].  
 In a recent study, Rahman et al. [34] demonstrated the use of human 
HepG2 cells encapsulated with alginate in plasma perfusion bioreactors. These 
cells were observed to maintain differentiated liver functions and were able to 
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reverse the loss of systemic functions after chemically-induced liver injury in a 
rabbit model including acid–base balance, cerebral oxygen consumption and 
systemic blood pressure.  
 Mai G et.al [35] demonstrated that alginate beads can be used to cryo-
preserve immortalized hepatocyte cell lines, thus providing an instant supply of 
cells to populate bioreactors. In previous studies, Aoki et al [38] established that 
the spleen was a good transplant site for encapsulated hepatocytes due to easy 
availability of nutrition and showed that intrasplenic transplantation of 
encapsulated mature hepatocytes into a rat model with 90% partial hepatectomy 
enabled the animal to survive without the need for immunosuppresion [39]. They 
also observed rapid liver regeneration after the transplant. Minimal fibrotic 
response but with no immune response was observed from the host despite the 
fact that alginate was a foreign body.  
 Alginate encapsulation is not restrictive of cell type and can also be used 
to develop three dimensional co-culture systems as demonstrated by Gao et.al 
[40]. In their studies, xenogeneic transplants of a co-culture mix of primary rat 
hepatocytes and islets into mice were found to functionally out-perform 
hepatocytes or islets encapsulated separately. 
4.2 Encapsulation Techniques 
Three different techniques were used to encapsulate the hepatic progenitor 
cells in alginate: 
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4.2.1 “Cannon-Ball” Method 
In this method, the alginate solution was drawn up in the syringe and 
dropped from a height of 2-3 cm into a receiving bath containing 125mM CaCl2 
solution. The droplets instantly gelled to form 3-5 mm diameter beads. 
Experiments performed with this method revealed that the encapsulated cells 
died within several days of encapsulation presumably secondary to a lack of 
nutrition due to the huge diffusion distances involved. Though this method had 
the advantage of maximum control and minimum stress on the encapsulated 
cells, it was abandoned for alternative methods that would produce beads with 
smaller dimensions. 
4.2.2 Air-Jet Encapsulation Method 
A controlled air stream was used to make alginate beads in this system. A 
wall air outlet was fitted with a filter and an air valve with a control mechanism 
(kindly provided by Dr. Bob Dennis, UNC-Chapel Hill). The syringe filled with 
cells suspended in 2% alginate solution was connected to a peristaltic pump. 
(Figure 4-1)  
The jet of air at a rate 20L/min was concentrated on the outlet of the 
syringe such that the expelled solution would be broken into tiny droplets that 
would fall into a solution of CaCl2 held in a beaker below. The system was 
arranged so that the tip of the syringe was about 2-3 cm above the top level of 
the CaCl2 solution.  
 The pumping rate was set at 2 ml/min. The sodium alginate droplets from 
the syringe were reduced to 300-500 µm droplets depending on the pump and air 
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flow rates. These micro-droplets were instantly converted to solid beads of 
calcium alginate upon contact with the CaCl2 solution in the beaker, thus 
encapsulating the progenitor cells within them. The calcium chloride solution was 
constantly stirred to prevent the beads from sticking to each other. 
 
Figure 4-1: Air-Jet Encapsulation System 
  
4.2.3 Electrostatic Encapsulation Method 
 Cell encapsulation was also performed using an electrostatic bead 
generation apparatus (Figure 4-2) (81). In this setup a high electrostatic potential 
was used as the operating force to break the flow into tiny droplets. The syringe 
was loaded onto a syringe pump (Braintree Scientific BS-8000, Braintree, MA) 
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and arranged such that droplets ejected from the angiocatheter fell orthogonally 
into the receiving bath. 
Figure 4-2: Electrostatic Encapsulation System 
 
 The receiving bath was a 250mL glass beaker filled with 125mM CaCl2 
solution. The syringe was fitted with a 24 gauge angio-catheter soft tip. The 
angiocatheter was pierced at the hub with a 23 gauge needle to serve as the 
positive electrode in the electrostatic casting process. The distance from the 
angiocatheter tip to the surface of the CaCl2 was fixed at approximately 2.5 cm. 
Pump flow rates were set within the range of 0.75 to 1.5 ml/min. A grounded 
electrode was immersed in the CaCl2 receiving bath. An electrostatic potential 
was developed across the angiocatheter tip and CaCl2 bath by a high-voltage DC 
source (Spellman model RHR30PF30, Hauppauge, NY) in the range of 3.8 to 6 
kV depending on the bead size required. 
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 Bead size was controlled by adjusting the applied potential and pump flow 
rate. When the syringe pump was turned on in the presence of the high 
electrostatic potential, the expressed sodium alginate solution was pulled away 
as tiny droplets that polymerized into solid calcium alginate immediately upon 
contact with the calcium chloride solution. 
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4.3 Results 
4.3.1 Hepatic Progenitor Cell Encapsulation 
 Figure 4-3 shows transmission microscopy images of hepatic progenitor cell-
containing alginate beads with differing diameters (HPCs: 1x106 cells/ml initial 
concentration) produced using the Air-Jet encapsulation method (4-3a) and the 
Electrostatic encapsulation method (4-3b, c). These images demonstrate the overall 
spherical nature of the bead, range of bead diameter production and the ability to 
generate beads containing the progenitor cell population. The cells are distributed 
throughout each alginate bead. The beads in Figure 4-3a and 4-3c have a diameter 
of approximately 400 µm and the bead in Figure 4-3b has a diameter of 
approximately 200 µm. This is proof that with both these methods we were able to 
generate beads with controllable diameters. A noticeable irregularity in the bead’s 
shape is a small tail generated on one end of the bead possibly due to the shear at 
the needle tip. 
 The Air-Jet system however suffered from operator inaccuracies in 
concentrating the air stream over the ejection port. This sometimes resulted in non-
uniformity in bead size and shape. There was tremendous variability between 
encapsulations depending on the operator’s hand position and movement. Another 
major concern was the shear stresses that the cells were exposed to with this 
method. Upon experimentation very little metabolic activity was demonstrated in 
cells encapsulated using this method. This finding necessitated research into other 
possible encapsulation techniques. 
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 The electrostatic encapsulation method had more stability and resulted in 
improvements with respect to uniformity and reproducibility. In long-term culture 
(beyond 3 weeks) the alginate beads maintained their physical characteristics (e.g. 
shape).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3: Hepatic Progenitor cells encapsulated in sodium alginate beads  
(a) Using the Air-jet system and (b, c) The Electrostatic system. Mag: 10X 
 
 
 
 
 
b c 
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4.3.2 Assay for Cellular Viability using Confocal Microscopy 
 Viability of encapsulated hepatic progenitor cells generated using the 
Electrostatic method was determined by confocal microscopy using the Mitotracker® 
dye which is incorporated into the mitochondria of living cells.  
Figure 4-4: A series of confocal images of HPCs within an alginate bead. Mag: 10X 
 
 The encapsulated cells remained viable for the duration of the experiment 
(day 0-21 in culture). Figure 4-4 shows confocal images of the encapsulated cells 
stained with Mitotracker®. The images were in consecutive focal planes 7.9 µm 
apart. There is no evidence of cell death within the core of the bead.  
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4.3.3 SEM to Analyze Bead Morphology 
Figure 4-5 shows a SEM micrograph of an alginate bead produced with the 
electrostatic encapsulation method. The image shows a spherical bead of 
approximately 150-200 µm with many surface imperfections. These are present 
because alginate is a hydrogel and undergoes shrinkage during the ethanol 
dehydration procedure. An uneven surface is partly due to the encapsulated cells 
that are protruding out of the surface (possibly due to expansion of the cell mass 
inside). 
Figure 4-5: Scanning electron micrograph of an alginate bead. 
 
 Two interesting features that can be observed in this picture are the 
depression at the front end of the bead and the tail at the far end. The depression 
represents the region where the droplet struck the CaCl2 surface and the alginate 
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thread that breaks away from the ejection port forms the tail. These morphological 
imperfections are of concern because of issues related to adequate nutrition 
distribution. A few iterations of the fixation protocol for SEM were performed. The 
standard SEM fixative solution had a chelating agent which dissolved the beads 
instead of fixing them. After a few iterations, the problematic agent was removed to 
fix the problem. 
 Transmission electron microscopy was also performed (Data not shown) on 
the beads. The TEM micrographs of beads showed cells with poorly defined intra-
cellular organelles. In subsequent experiments, this was found to be as a result of 
the TEM processing technique and not because of the encapsulation method. Cells 
that were obtained by breaking open the beads after encapsulation showed intra-
cellular structure. It was decided not to pursue TEM to image encapsulations 
because of these technical challenges. 
4.3.4 MTT Assay to Analyze Cellular Proliferation 
It was necessary to analyze the proliferation characteristics of the cells to make 
functional comparisons between encapsulated HPCs and those cultured on two 
dimensional collagen coated dishes. A colorimetric assay based on mitochondrial 
breakdown of MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] 
was used for this purpose. The assay results showed that there was considerable 
cell loss in the first few days after the cells were isolated. This can be attributed to 
the culture conditions that are more attuned to proliferation and differentiation of 
HPCs and not the freshly isolated heterogeneous cell population. The other factor 
contributing to this cell loss was the stress undergone by the cells during the initial 
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procedures (isolation, encapsulation etc.). After about day 6 in culture, the cells 
recovered from the initial insults and proliferation could be demonstrated by the 
increase in cell number. By about day 7 mature hepatocytes whose proliferation had 
been stopped secondary to the addition of DMSO (day 4), start dying. This decrease 
in cell number was compensated by the proliferating HPCs and there is only a slight 
depression in the cell growth curve. After about three weeks in culture, cells entered 
a stationary phase of their cell cycle. 
 
 
Figure 4-6: Growth characteristics of encapsulated and 2-D cultured HPCs.  
(MTT Assay) 
 
These characteristics were true for both encapsulated and non-encapsulated 
HPCs which proved that the encapsulation procedure did not have a long term 
impact on the growth of these cells. It also proved that the encapsulated cells were 
adequately nourished and there was no significant death due to necrosis. The 
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numbers from the viability experiments shown in Figure 4-6 were used to normalize 
the metabolic assays described below. 
4.3.5 Analysis of Hepatocellular Function of Encapsulated HPCs 
4.3.5.1 Urea Nitrogen Metabolism and Albumin Production 
The cells’ ability to undergo urea-nitrogen synthesis and their ability to 
produce albumin was studied to analyze hepatocellular function of the encapsulated 
HPCs. Figure 4-7 compares urea metabolism in the encapsulated hepatic progenitor 
cells versus a control (hepatic progenitor cells in routine tissue culture). This assay 
was evaluated at select time points during 2 weeks of culture and demonstrates 
persistence of urea metabolism during that time.  
Figure 4-8 represents a graph for albumin synthesis by encapsulated HPC 
over a period of two weeks. Albumin synthesis by the encapsulated progenitors 
occurred at a rate comparable to cells grown on control dishes. The data from both 
the urea nitrogen and albumin synthesis assays were normalized for cell number 
obtained using an MTT assay. 
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Figure 4-7:  Comparison of Urea Metabolism by encapsulated and control HPCs. 
 
Figure 4-8: Comparison of Albumin synthesis by encapsulated and monolayer HPCs. 
 
 
4.3.5.2 Periodic Acid Schiff’s (PAS) Assay for Glycogen Storage 
 The Periodic Acid Schiff’s (PAS) assay demonstrates glycogen storage within 
a cell; another functional characteristic of hepatocytes. This is a complementary 
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assay to evaluate the impact of the electrostatic encapsulation process on the 
hepatic progenitor cell viability and metabolic function. Glycogenesis (conversion of 
glucose to glycogen) and its subsequent storage is a primary function of 
hepatocytes. Glycogen particles are found in the cytoplasm of hepatocytes and are a 
marker for functional maturation. Figure 4-9 shows a histological image of a mature 
hepatocyte depicting glycogen particles in the cytoplasm. 
This experiment helped analyze if the encapsulated progenitors were 
proceeding along a hepatic-differentiation pathway or undergo stress induced de-
differentiation and loss of function. 
Figure 4-9: Glycogen particles in the cytoplasm of a mature hepatocyte. 
(Image Source: http://www.humpath.com) 
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Figure 4-10: Fluorescence image of PAS staining of encapsulated HPCs.  
 
 Glycogen stores inside the cell are oxidized into aldehydes by periodic acid 
during the procedure. The aldehydes react with the Schiff’s reagent forming a 
colored final product. Figure 4-10 demonstrates encapsulated cells stained for 
glycogen particles using the PAS assay 7 days post-encapsulation. Alginate beads 
in the image have a diameter of approximately 200µm based on confocal 
measurements. Encapsulated HPCs were also observed to have glycogen stores 
that persist beyond 3 weeks in culture. 
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4.4 Conclusion and Future Plans 
 This novel demonstration of electrostatic encapsulation of hepatic 
progenitor cells provides a successful step in creating a cellular niche that 
supports the ex vivo culture of somatic-derived progenitor cell (or stem cell) 
populations. The three dimensional character of the encapsulated beads allows 
us to increase the cell density compared with traditional tissue culture 
experiments. This process also favors development of an optimal 
microenvironment for the hepatic progenitor cells. The encapsulation process 
provides a framework or matrix for the hepatic progenitor cells thus allowing them 
to play a dynamic role in developing an ideal three dimensional architecture. 
Potential applications for this method of progenitor cell encapsulation include 
drug screening and the development of bioreactors. 
4.4.1 Future Plans 
 The results from the ELISA and the PAS assays allow us to raise exciting 
scientific questions about the phenotypic changes in the encapsulated cells 
during later time points in culture. Experiments are also currently ongoing to 
incorporate alginate encapsulated cells in NMR compatible bioreactors. This 
allows the device to be used as a perfusion bioreactor and also to study cell 
metabolites during drug screening.  
 Future experiments will build on these results and try to improve the 
encapsulated cell viability.  The immediate plan is to translate the macroscale 
encapsulation experiments described herein to the microfluidic platform to 
 45 
enhance viability by reducing fluid stressors and also to reduce the operating 
volume and cell number requirements.  
 The microfluidic encapsulation device will also utilize natural extracellular 
matrices like collagen as encapsulation substrates to provide cell-matrix 
interactions that are critical to progenitor cell proliferation and differentiation. This 
revolutionary “Lab-on-a-chip” device will also greatly enhance analysis of effects 
of drugs/cytokines etc. on progenitor cells cultured on 3-dimensional matrices by 
reducing their quantity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 Microfluidic Encapsulation System 
5.1 Microfabrication and BioMEMS 
Recently, there has been huge progress in the fields of microelectronics, 
microfabrication and micromachining technologies. These are collectively now 
called MEMS and its applications in biomedical engineering have spurned a new 
field known as BioMEMS. The technology can trace its origins to computer chips 
manufacturing processes and companies that were trying to make them more 
powerful and less expensive. This has already made its impact on decreasing the 
cost of technology in extensively used devices like computers and hand held 
devices. [82] 
The field of medical diagnostics has been searching for the development 
of novel devices which offer great control on functionality at a reduced cost. The 
new field of BioMEMS has enabled researchers to apply these concepts to varied 
areas in biotechnology and clinical medicine. 
5.2 Microfluidics  
Microfluidics is a multidisciplinary field combining principles of physics, 
chemistry, engineering, biotechnology and the new field of BioMEMS which 
enables creation of devices with micron-sized dimensions. [83]. It can be defined 
as the science of manipulating nanoliter or microliter volumes of fluid with great 
precision and control. The field is relatively new, making an emergence in the 
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1990s and has generated great interest in creation of a myriad of “Lab-on-a-chip” 
devices. This technology can allow for the creation of micro-chemical reactors, 
micro/nano sensors and actuators to single cell analysis systems and high 
throughput bio-assays.  
5.3 Fluid Behavior at the Microscale 
The dominant forces at the microscale are very different from those 
experienced in everyday macroscale situations [84]. Precise understanding of 
these physical phenomena is critical for miniaturization. It would be erroneous to 
assume that a large scale device would exhibit similar characteristics when 
shrunk down to micron dimensions [85]. The phenomena that play a major role in 
a microfluidic environment are laminar flow, diffusion, fluid resistance, effect of 
surface to volume ratio and surface/interfacial tension. 
Flow at the microscale is always linear because of the dimensions of the 
microchannels [86]. This effect is quantitatively explained by the most important 
dimensionless number in fluid dynamics, the Reynolds number (Re). In fluid 
mechanics, the Reynolds number is the ratio of inertial fluid forces (ρvs) to 
viscous forces (µ/L). This ratio thus quantifies the relative importance of these 
two forces for given flow conditions. Thus, it is used to identify different flow 
regimes, such as laminar or turbulent flow [87]. The Reynolds number (Re) is 
less than 2300 for laminar flow and the flow becomes turbulent as Re 
approaches 2300. It is mathematically represented as follows; (‘L’ being the 
principle dimension of the flow chamber) 
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Due to the small dimensions of microfluidic chambers the Reynolds 
number is typically much less than 100 [88]. This explains the dominance of 
laminar flow at the microscale. 
The laminar flow profile provides us great control over fluid flow and the 
ability to precisely manipulate fluid particles inside the microchannel architecture. 
However this laminar flow regime is problematic in the building of chemical 
reactors because of insufficient mixing at the microscale [89, 90]. The other 
possibility is the creation and transportation of discrete droplets of fluid that can 
function as micro-reactors and sensors. As explained later in this document, 
these fluid droplets can also be used to hold cells, protein, growth factors etc. for 
purposes of tissue engineering. 
The surface to volume (SAV) ratio also plays a significant role in 
microchannels. The surface to volume ratio increases by orders of magnitude 
compared to macroscale situations because of the dimensions at the microscale. 
This phenomenon can be observed in “Lab-on-a-chip” chemical reactors. High 
SAV causes reactions to occur faster at the microscale due to faster migration of 
reactants inside the reaction chamber. The high SAV also provides for improved 
heat transport characteristics. For example, rapid removal of excess heat in 
microchannels makes capillary electrophoresis more efficient (102). 
5.4 Surface/Interfacial Tension 
Surface tension is an effect within the surface layer of a liquid that causes 
that layer to behave as an elastic sheet. This is a very commonly observed 
phenomenon in everyday life. A layer of oil on a puddle of water, the water strider 
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walking on water and dew drops on leaves are all due to the effects of surface 
tension. The effects of interfacial tension are greatly pronounced at the 
microscale because of the small dimensions involved that increase the surface 
free energy of the fluid. This leads to effects like capillarity where fluids can be 
moved through a microchannel for long distances without any active pumping 
mechanism. The smaller the channel dimensions the longer the fluid travels. In 
nature this is observed in plants that use channels a few nanometers wide to 
pump water and nutrients from their roots to the leaves. The increased effects of 
interfacial tension can also be harnessed to cause flow focusing in a 
microchannel as explained in detail later in this document. 
5.5 Biological Applications of Microfluidics 
Advances in microfabrication techniques and the invention of the “soft 
lithography” process [91] has led to this technique being increasingly applied in 
biology and has created a new field called Biomicrofluidics. The applications of 
biomicrofluidics are endless; from microscale perfusion cell culture systems to 
DNA purification systems to high throughput bio-assays. The advantages are 
ease of manufacture, very small operating volumes usually in microliters and 
nanoliters and faster thermal and chemical transfers due to the high surface to 
volume ratios.  
The small operating volume is highly favorable in the drug testing industry 
where it could result in huge financial savings by reducing the amount of 
drug/compound needed for a test. One of the biggest applications has involved 
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biomicrofluidics where it is possible to mimic microscale tissue structures like 
capillaries and cell-cell junctions. [92] 
Such systems can also provide ideal environments for cell culture and 
fluidic behavior similar to in-vivo environments. Biomicrofluidics has numerous 
applications in the field of tissue engineering including precise cell patterning, 
control over topography and in microscale bioreactors and biohybrids. 
5.6 Microfluidic Devices- Design and Fabrication 
Microfabrication methodologies originally designed in the field of 
integrated circuit (IC) design and microelectronics have revolutionized the field of 
microfluidics. The most popular technique for the manufacture of biomicrofluidic 
devices involves photolithography to manufacture of the silicon masters followed 
by soft lithography to create a mold of the design using an elastomeric material. 
5.7 Photolithography 
Photolithography (also optical lithography) is a process used in 
microfabrication to selectively remove parts of a thin film. It uses light to transfer 
a pattern from a photomask to a light-sensitive chemical (photoresist) on the 
substrate. A series of chemical treatments then engraves the exposure pattern 
into the material underneath the photoresist.  
There are two kinds of Photoresists: Positive tone and Negative tone 
photoresists depending on their light interaction property. Positive tone resists 
become soluble in developer solution upon exposure thereby leaving behind the 
unexposed regions. Negative tone resists harden upon exposure to light and the 
unexposed regions wash away when exposed to developer solution. The only 
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limiting factor in the fabrication process is the resolution obtainable in the 
photomask printing process. The schematic of the lithography process is shown 
in Fig 5-1. 
Figure 5-1: Photolithography Process 
(Ref: http://britneyspears.ac/physics/fabrication/Image46.jpg) 
 
5.8 Soft Lithography  
Soft lithography refers to the technique of replicating the structures on a 
patterned substrate using shape conforming, curable elastomeric materials. The 
process involves pouring a two-part polymer (mix of elastomer and curing agent) 
over the micropatterned substrate (usually silicon) and allowing it to cure. 
The cured elastomer will retain the pattern on the substrate and can be 
peeled off. If the substrate is manufactured by photolithographic processes, a 
negative tone photoresist is used for forming a depressed structures and a 
positive tone for raised features in the elastomer. The schematic for a typical 
softlithographic process is shown in Fig 5-2. 
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Figure 5-2: Soft Lithography Process 
Currently, the most commonly used material for biomicrofluidics is 
Polydimethylsiloxane (PDMS). The popularity of PDMS is due to its great 
material properties. Cured PDMS is flexible but sturdy enough to manipulate. It is 
biocompatible as its preparation does not involve any toxic solvents subsequently 
allowing it to be used in cell culture. It is also highly inert and can thus be used to 
build devices that are used in bioassays and for testing of compounds.  
The other important property of PDMS that is beneficial when used in 
conjunction with cells etc. is its gas permeability. PDMS is highly gas permeable 
and this prevents the occurrence of hypoxia which is commonly observed with 
enclosed cell culture designs. It is also optically transparent and is usable in even 
highly sensitive microscopy techniques like DIC imaging and fluorescence. 
Enclosed Channel  
Structure 
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5.9 PDMS - Wetting Characteristics 
Cured PDMS is hydrophobic in nature with a contact angle of about 119o 
[93]. This property of PDMS has its advantages and disadvantages when used in 
biomicrofluidic applications. When used as a flow chamber, its wetting property is 
advantageous because it prevents the fluid constituents from sticking to the 
PDMS walls and clogging the channels. Channel obstruction is an enormous 
problem due to the small features of microfluidic devices. 
With PDMS devices being increasingly used as cell culture vessels and 
scaffolds, the hydrophobicity of native PDMS requires to be altered. The wetting 
properties of the PDMS can be modified by either exposing it to oxygen plasma 
[94] or by coating the surface of the PDMS with a material that can present a 
binding domain [95]. It is now possible to precisely pattern such binding sites on 
the PDMS thus allowing the investigator to perform diverse analysis on a single 
microfluidic chip. 
5.10 Droplet Generation at the Microscale 
Uniformly shaped droplets can be formed at the interface of two 
immiscible fluids within a confined microfluidic channel. This phenomenon is due 
to the basic energy conservation principles and is dependent on the geometry of 
the interface and the surface characteristics [96] of the microchannel walls. Two 
fluid forces are active at a fluid junction in a microfluidic channel of two 
immiscible fluids. One is the viscous force that tries to maintain a laminar flow to 
the outlet because of the low Reynolds number environment. The other is the 
capillary force trying to minimize total surface of interaction between the two fluid 
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phases by splitting one into spherical shaped droplets which represents the least 
surface area of all shapes. 
5.11 Capillary Number (Ca) 
Microfluidic droplet generation can be quantitatively explained by a 
number called the Capillary number (Ca). In fluid dynamics, the capillary number 
expresses the relative effect of viscous forces and interfacial tension at the 
interface between two immiscible fluids. It can be defined as: 
 ;  
 
 
 
 
The size of the generated droplets can be controlled by the capillary 
number and from this equation it is obvious that this can be simply achieved by 
varying the applied fluid velocities. 
5.12 Mechanism of Droplet Generation 
Fig 5-3 shows a simple “T junction” interface between two immiscible 
fluids A and B.  As explained above, two forces act on the fluid stream A. The 
viscous drag of the fluid tends to push it towards the outlet in a linear stream. 
This however impedes the laminar flow pattern of Fluid-B. This competition of the 
viscous forces leads to a slow “pinching” or “shear focusing” effect that causes 
elongation of Fluid-A until it reaches its stability limit and pinches off into droplets. 
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Surface interactions of Fluid-A with Fluid-B and the channel walls, the capillary 
forces shape the fluid packet into a spherical shape to conserve surface energy. 
 
 
Figure 5-3: “T-junction” depicting droplet generation at the interface of two 
immiscible fluids 
 
5.13 Droplet Generation – Literature Review 
The study of interface driven motions of fluid and fluid breakup into 
cylinders and other shapes (97) began with the work of Plateau and Lord Raleigh 
(98-100). This has historically involved break up of a fluid stream in another bulk 
fluid where the two fluids are immiscible with one another. The resultant droplets 
had a huge drop size distribution. The production of mono-disperse droplets has 
generated much interest. This is partly due to the need for such a tight size 
distribution in biological applications. Most of the work has focused on two 
B 
B 
A 
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modalities for droplet generation at the microscale: “T-junction” geometry [101] or 
a multi-tiered flow focusing device (FFD) using micro-capillary architectures 
[102]. As explained above, the T-junction employs a shear-rupturing mechanism 
brought about by the competition between viscous forces at the junction. Many 
different modifications of the T-junction have been developed to achieve maximal 
focusing of fluid forces [101]. The possibility of accurate spatial prediction of 
these micro-reactors as well as the capability to form dynamic patterns [103] has 
also spurred interest in this field. The microencapsulation of biological materials 
(proteins, growth factors etc.) in liquid vesicles has also gained interest [104]. 
The dynamics of the microfluidic environment also allow for production of 
polymer particles from a pre-polymer solution [105, 106]. 
Although the possibility of cellular encapsulation in polymer particles 
inside a microfluidic shear focusing device has been discussed earlier [118, 119], 
not much has been accomplished in the scientific community. This is in part due 
to the unavailability of biocompatible materials that are capable of being 
manipulated in this environment to produce successful encapsulation. 
Much of the need for cellular encapsulation is in the fields of tissue 
engineering and drug testing. The creation of spherical polymer particles with 
embedded cells would allow for 3-dimensional cell culture, cell transplants, drug 
metabolite analysis. Advantages of the microfluidic platform for cellular 
encapsulation include the necessity for lower operating fluid volumes, lower cell 
stressors and the possibility of downstream analysis, all on a single chip. 
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5.14 Project Rationale 
As mentioned earlier, a new system was required for encapsulation of 
sca-1+ hepatic progenitor cells (sca-HPCs) for purposes of cell culture and 
delivery. Microfluidic encapsulation systems that require low operating volumes 
on the order of milliliters and exerting lower mechanical stresses on cells was the 
perfect alternative. 
Conventional cell encapsulation approaches (macro or micro scale) utilize 
natural matrices like alginate and synthetic materials like Poly-L-lactic acid 
(PLLA) etc. that have been approved by the FDA for use as suture materials. 
Since encapsulation of hepatic progenitor cells was the major rationale behind 
this project, it was hypothesized that collagen would be the ideal encapsulation 
matrix. Encapsulation of cells in a collagen droplet requires environmental 
conditions that are favorable to collagen gellation within the microchannel 
framework to eliminate the need for further batch processing [106]. 
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5.15 Materials and Methods 
5.15.1 Mask Design 
The channel design was drawn using Adobe Illustrator software. A single 
continuous phase channel was split to ensure that the oil arrives at the junction at 
the same time from the top and the bottom. The output channel was made long 
and tortuous to keep the generated beads inside the microfluidic network to allow 
for complete gellation. The device concept is shown in Fig 5-4. 
Figure 5-4: Microfluidic junction showing bead generation 
 
5.15.2 Fabrication of Silicon Master 
The channel design was printed using a high resolution emulsion printer 
on transparencies. SU-8 being a negative tone photoresist, most of the UV light 
needs to be blocked by the mask during photolithography. The channels were 
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thus drawn clear on a black background to allow light to only pass through the 
design features. 
A 3” silicon wafer is cleaned with acetone and isopropyl alcohol (IPA) 
twice and dried on a hotplate. A thin coat of SU-8 2050 photoresist is applied 
using a spin coater. The spin speeds are determined using the graph shown in 
Fig 5-5 based on the desired height of design features. After an initial bake, the 
photoresist is exposed to near UV light through the photomask.  
Since SU-8 is a negative photoresist, this causes the exposed regions to 
become less acidic. Upon development using an alkali solution, the unexposed 
regions of the photoresist get washed away leaving behind the microscale design 
features. 
Figure 5-5: SU-8 spin speed versus thickness  
Ref: http://microchem.com/products/su_eight.htm 
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5.15.3 Soft Lithography 
Soft lithography refers to the technique of using elastomeric materials like 
Poly-di-methyl siloxane (PDMS) to conform them to structures on a master 
template. PDMS has been the material of choice for building microfluidic devices 
due to its excellent conformance to patterned surfaces. It is also optically 
transparent, inert and gas permeable leading to its usage in the field of 
biomicrofluidics. 
To build the encapsulation device, PDMS elastomer mixed with curing 
agent (ratio of 10:1) was degassed in a vacuum chamber and cast on the silicon 
wafer. It was placed on a hotplate and allowed to cure at 80oC for three hours. 
The PDMS mold was peeled off the wafer after curing and the inlets and outlets 
were cored out for channel access. 
5.15.4 Plasma Treatment 
Requirement of a closed channel architecture necessitated sealing of the 
bottom of the channel network in order to withstand the fluid pressure. This was 
achieved by bonding the PDMS mold to a glass slide. Bonding was achieved by 
briefly exposing the PDMS and the glass slide to oxygen plasma. This formed an 
irreversible bond between the PDMS and the glass slide. In later experiments, 
the glass slide was replaced by a flat PDMS sheet to provide a uniform 
hydrophobic environment inside the microchannel. 
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5.15.5 Fluid Phases 
In our previous experiments with encapsulation, calcium alginate was 
used as the encapsulation matrix. It was postulated that since cell-ECM 
interactions are critical to maintenance of cellular function, collagen would serve 
as a better substrate for encapsulation. Vitrogen™ (Cohesion Technologies, Palo 
Alto, CA) was chosen as the distributed phase because of its gellation properties. 
Vitrogen™ is sterilized, 97% pure, bovine Collagen-I with the rest comprised of 
Collagen-III. It forms a stable hydrogel at a pH 7.0 and at about 37oC. Olive oil 
was chose as the continuous phase in the bead generation process. It was 
chosen because it does not swell the PDMS substrate.  
The Vitrogen™ solution is prepared according to the manufacturer’s 
protocol. The cells to be encapsulated are suspended in the collagen solution at 
a pH of about 7.0. Care is taken to avoid air bubbles. The ECM/cells solution is 
drawn into 1cc syringe. Olive oil is drawn into another 1cc syringe and both 
syringes are fixed on micro-flow syringe pumps. 
5.15.6 Microfluidic Device Construction and Testing 
The pump is connected to the microfluidic device through tubing inserted 
into the cores at the inlet ports. The device was demonstrated to be free of leaks 
and could bear the operating fluid pressure without failure. This was verified by 
flowing colored solutions through the channels and observing the PDMS edges 
under a microscope. The PDMS device was cleaned using ethanol followed by 
sterile water. It was allowed to dry under UV light in a laminar flow hood. The 
working concept was first verified by flowing two colored (blue and red) miscible 
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solutions. This is shown in Fig 5-6. Since there is no interfacial tension between 
the two phases and due to the poor mixing characteristics of the microfluidic flow, 
the two solutions flow parallel to each other. 
Figure 5-6: Flow of miscible fluids in a device with 200 µm wide channels. 
5.15.7 Device Operation 
At the junction point of the three fluid streams, the interfacial tension 
(between collagen and oil) and the hydrophobic environment of the PDMS 
chamber preferentially pinches off the collagen/cells stream into spherical 
droplets. The tortuous outlet network will be gently heated to 37oC. This causes 
the collagen droplets to gel as they travel through the outlet channel and the 
gelled beads are tapped out of the cored outlet port.  
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The bead size is a function of channel dimensions, fluid viscosity and the 
flow rate. Thus for a given device and fluid phases the bead size can be easily 
regulated by adjusting the flow rates of the pump. This also offers us control over 
bead production rate via adjustment of the flow rate of the collagen solution while 
simultaneous changes can be made in the oil flow to maintain a constant bead 
size. 
The generated beads have a tendency to coalesce as soon as they leave 
the microfluidic environment. To prevent this, it was necessary to saturate the 
bead outer surface area with surfactant molecules. This reduced the interfacial 
tension between the collagen solution and the olive oil and prevented bead 
coalescence. Tween-20 mixed with the olive oil at a concentration of 2-3% w/w 
was used as the surfactant. It was chosen because of its widespread usage in 
biological processes and its ease of availability. 
5.15.8 Effect of PDMS Plasma Treatment on Immiscible Fluid Flow 
When two immiscible fluids intersect at a microfluidic junction, one of the 
fluids is expected to “pinch off” into droplets. This is determined by the interaction 
of the two fluids along with the wetting properties of the fluid chamber.  
Hydrophilic channels form oil droplets and hydrophobic channels are 
better suited for pinching off the aqueous phase. Upon plasma treatment for 
purposes of bonding, the natively hydrophobic PDMS becomes hydrophilic. This 
caused the oil phase to pinch off into droplets. This is shown in Fig 5-7. 
The PDMS mold was allowed to recover its hydrophobicity at room 
temperature for 3 days to prevent this occurrence. After recovery, it was 
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observed that the aqueous phase was being “pinched off”. This is shown in Fig 5-
8. 
 
Figure 5-7: Oil droplets being “pinched off” in a hydrophilic environment.  
Channel Width: 100 µm. Mag: 10X 
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Oil 
Oil 
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Figure 5-8:  Droplet generation in a hydrophobic environment. 
Channel Width: 100 µm. Mag: 10X 
a. Aqueous phase being “pinched off” in a hydrophobic environment. 
b. Generated droplet moving through the outlet channel. 
a 
b 
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Another phenomenon that can be observed in Fig 5-8 is the “plug like” 
nature of the generated droplet. This was because of the hydrophilic nature of 
the bottom glass slide. This exerts a drag on the produced droplet thus causing 
elongation. It is thus evident that a uniform hydrophobic environment is needed 
to generate spherical beads. This was accomplished by using a flat sheet of 
PDMS made on a non patterned silicon wafer instead of the glass slide as the 
bottom of the microfluidic device. 
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5.16 Results 
5.16.1 Collagen Bead Generation 
Vitrogen™ beads were produced using the same procedure as described 
above. Fig 5-9 (a) is a high speed camera image showing Vitrogen™ beads 
being generated using olive oil as the dispersed phase. Fig 5-9(b) shows the 
beads that were collected from the outlet port after allowing for gellation. 
 
Figure 5-9: Generation of Vitrogen™ beads at a “T-junction” 
Channel Width: 100 µm. Mag: 10X 
a. Image of Vitrogen™ droplet being generated. 
b. Collagen beads collected at the outlet port 
5.16.2 Control over Bead Size 
Figure 5-10 shows a graph of bead size versus flow rate of the continuous 
and discrete phases. The bead sizes increase with increase in the flow rate of 
the collagen solution and decreases with increased flow rate of the oil phase. 
a b 
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This is predictable because the viscosity of the oil phase is a dominant force at 
the junction. Increasing the flow rate of the oil phase increases the droplet 
generation rate thus resulting in smaller droplets. Increasing the flow rate of the 
collagen solution ensures increased availability of the dispersed phase at the 
junction. This results in increased droplet size for the same flow rate of the oil but 
at a faster droplet generation rate. 
Figure 5-10: Effect of fluid flow rates on collagen bead size 
 It is possible to create beads with sizes ranging from 50–250 µm. The 
bead diameter for encapsulation of cells needs to be 100-150µm to provide for 
optimal number of cells per bead and to maintain nutrient diffusion distances 
below the “diffusion barrier”. 
5.16.3 Design Modifications 
Fig 5-11 depicts a modified junction architecture where the junction is 
expanding into the outlet. The channel height in this design was also increased to 
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150 µm from 100 µm. These changes were made to optimize bead shape inside 
the channel architecture and to overcome the fluidic resistance of the viscous oil 
phase.   
As depicted in Figure 5-8(b), larger beads are confined and tend to 
elongate inside the channels, attaining a spherical shape only after reaching the 
outlet. The other issue associated with flowing viscous fluids in a microchannel 
was the increased fluidic resistance. This caused the oil phase to sometimes 
push into the collagen inlet channel at higher flower rates. 
Figure 5-11: Expanding Outlet with Increased Channel Height 
 
Since the target bead diameter was 100-150 µm and bead gellation was 
required to happen inside the channel confines, it was necessary for the beads to 
attain a spherical shape once they were generated. This was achieved by 
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increasing the channel height to prevent bead elongation. Vitrogen™ beads were 
observed to instantaneously attain a spherical shape in the channels with 
increased height, (Fig 5-12). 
Fluidic resistance is directly related to the channel dimensions and 
decreases with increasing channel width and height. Increasing the channel 
height also thus decreased the resistance of the oil phase and solved the reverse 
flow problems. 
Figure 5-12: Bead generation at exit orifice 
 
The expanding outlet channel also caused the flow focusing effect to be 
pronounced at the junction of the two fluid phases. In a simple “T-junction” design 
the viscous collagen phase would sometimes be “pinched off” further 
downstream instead of at the junction. The expanding geometry caused 
predictable generation of collagen droplets at the junction. Using simulations it 
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has been shown (116) that such geometry would cause the maximum fluid 
velocity to occur at the exit orifice. 
5.16.4 Cellular Encapsulation in Vitrogen™ Beads 
 LA-7 rat mammary tumor cells were successfully encapsulated inside 
mono-disperse collagen beads. To provide for additional gellation time, beads 
were confined within the microchannel geometry for 1 hour inside a 5% CO2/95% 
air incubator. A challenge with this system has been that the beads continue to 
possess a liquid core. Figure 5-13 depicts collagen beads inside the 
microchannel framework.  
 
Figure 5-13: Image of cells encapsulated in Vitrogen™ beads.  
(a) 10X and (b) 20X image of collagen beads showing encapsulated cells (Red arrows). 
 
5.17 Discussion 
 These experiments are a novel description of microfluidic encapsulation of 
cells inside collagen microspheres. The system could consistently generate 
mono-disperse Vitrogen™ beads encapsulating the cells as demonstrated in the 
a b 
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results. With this system it is also possible to accurately control the bead 
dimensions by adjusting the flow rates of the continuous and dispersed phases. 
 The generated beads have uniform spherical shape and this symmetry is 
important to permit predictable and uniform chemical and heat transfer though 
the beads. This also permits solute transport to and from the cells. The cells are 
well within the “diffusion barrier” [67] of ~150 µm and this prevents hypoxia in the 
encapsulated cells. 
 Alternative approaches to microfluidic droplet generation involved harsh 
chemical reagents or UV photo-polymerization to cause gellation of droplets. 
These steps render the techniques incompatible with cells. Recently Lee et.al 
(107) have demonstrated successful microfluidic cell encapsulation in alginate 
beads. Though this is a major step towards microfluidic cell encapsulation, the 
long term effects of the organic reagents utilized during the encapsulation 
process on encapsulated cells is yet to be established. 
 The Vitrogen™ encapsulation protocol is completely benign and none of 
the system components have a deleterious impact on the encapsulated cells. 
The gellation is completely biocompatible and does not require any harsh 
processing steps like UV-exposure. 
 In conclusion, this demonstration of microfluidic collagen encapsulation 
creates a three dimensional microenvironment for the encapsulated cells. 
Potential applications for this method of cell encapsulation include drug 
screening at the microscale and the micro-bioreactors. This microfluidic 
technique requires very low operating volumes and can thus be used for 
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encapsulating rare cell types like hepatic progenitor cells for purposes of 
transplant. These applications are explained in detail in the next section. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 Conclusions and Future Work 
6.1 Conclusions 
 Three different tissue engineering approaches for liver tissue engineering 
are described in this dissertation. The study revolved around developing novel 
strategies for 3-dimensional culture and in-vivo delivery of bipotent hepatic 
progenitor cells (HPCs) isolated from naïve adult mice.  
 The first approach was the creation of cell+scaffold “biohybrids” to provide 
an optimal 3-dimensional culture environment for the HPCs. As detailed in 
Chapter 3, this investigation involved culturing HPCs on BD™ collagen 
composite scaffolds. These scaffolds have a high porosity and an optimal pore 
size distribution for cellular in-growth. 
 It was established that both mature hepatocytes and hepatic progenitor 
cells were able to proliferate on this matrix. The study also investigated the 
maintenance of hepatic function in HPCs seeded on the collagen scaffolds. This 
was accomplished by analyzing their capability to produce protein and urea 
nitrogen. Loss of hepatic function was observed after 14 days in culture. It was 
felt that this was due to the heterogeneity of the HPC population. This created a 
need for further purification of this cell population to isolate the true hepatic 
progenitor cells from the contaminating non-parenchymal cells and other liver 
constituents like endothelial cells. The degradation properties of the scaffolds 
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were also found to be lacking. The scaffolds could not withstand the combined 
effects of the in-vivo environment and cellular contractile forces. They 
disintegrated in less than a week when loaded with hepatic progenitor cells and 
transplanted into the intraperitoneal space in mice. 
 Chapter 4 discusses in detail a cell encapsulation approach using calcium 
alginate microspheres. The rationale behind this approach was to create an 
immunoprotective barrier around the HPCs for purposes for cell delivery. It was 
established that the encapsulation system did not have an adverse impact on cell 
viability or function. Encapsulated HPCs produced urea and albumin at a rate 
comparable to cells in monolayer culture. They were also found to maintain 
differentiated functions like glycogen storage for long periods in culture.  
 The results from the viability experiments demonstrated a considerable 
loss in cell number in the first few days in culture. This cell death was attributed 
to the loss of non-parenchymal cells present in the population. The death was 
secondary to the culture conditions that are more attuned to the culture of hepatic 
progenitor cells. These results further emphasized the need for a purified cell 
population for purposes for tissue engineering and hepatic transplant. 
 Purification of the heterogenous HPC population using a stem cell marker 
Sca-1 yielded a bipotent sub-population (sca-HPCs) that is capable of robust 
proliferation and differentiation into mature hepatocyte and biliary phenotype. The 
relative rarity and fragility of the sca-HPCs necessitated the development of a 
tissue engineering technique that had low operating stresses and operating 
volumes. This led to the development of a microfluidic “Lab-on-a-Chip” platform. 
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 Chapter 5 details this microfluidics/bio-MEMS approach applied to 
encapsulation of cells in collagen microspheres. This involved manipulating two 
viscous, immiscible fluid phases in microchannel architectures to create an 
emulsion of one phase in the other. It was achieved by harnessing viscous and 
capillary forces that are dominant at the microscale. 
 Vitrogen™, a mixture of 97% collagen Type-I and 3% collagen Type-III 
was used as the distributed phase and olive oil (or its derivatives) was used as 
the continuous (lipid) phase. Handling the viscous collagen solution necessitated 
extensive modification of existing droplet generation technologies and iterative 
fine tuning to get repeatable generation of collagen droplets.  
 Results demonstrate reproducible generation of Vitrogen™ droplets that 
can be caused to gel in the microchannel framework. The system permitted 
precise control over droplet size by manipulating flow rates of the two fluid 
phases. This enabled creation of mono-disperse beads ranging in size from 50-
200 µm. Cells were also encapsulated in Vitrogen™ microcapsules thus creating 
micro-bioreactors for purposes of 3D cell culture, cell transplant and drug 
analysis. 
 The issue of incomplete gellation would be addressed by providing a 
framework wherein the collagen spheres can be provided with an outer shell that 
is capable of instant gellation. This would enable manipulation of the collagen 
beads outside the microchannel framework for purposes of cell culture and 
transplant. This will also permit replacement of the oil phase with culture medium 
to provide nutrition for the encapsulated cells. 
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 As expounded in this dissertation document, numerous challenges exist in 
creating a tissue engineering model for hepatic therapy from somatic-derived 
progenitor cells. Cell encapsulation approaches are a successful step in 
providing an optimal growth environment for these cells. This document adds to 
the existing knowledge of encapsulation methodologies and will assist further 
investigations related to liver tissue engineering and organ regeneration. 
6.2 Future Work 
6.2.1 Alginate Shell for Instant Gellation of Vitrogen™ Bead 
 The gellation time of the collagen solution is not instantaneous and is 
difficult to manipulate. The droplets maintain their spherical morphology and 
discrete nature until they are confined in the microchannel environment. The laws 
governing microscale physics cease to exist once the droplets exit the 
microfluidic environment. This causes fluid mixing and consequently droplet 
coalescence. This phenomenon can be prevented by the surfactant molecules 
but once the beads are removed from the oil phase they cease to hold their 
spherical shape. 
 Therefore there is a need to provide the beads with a mechanism that 
would provide for instant gellation. This can be achieved using sodium alginate 
as an outer shell. Allowing Ca2+ ions suspended in the oil phase to diffuse into 
the collagen droplets would cause the outer shell to gel thus encapsulating the 
liquid core. 
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 The design requires a simple upstream modification in the collagen 
channel. Two small channels of alginate feed into the collagen channel on either 
side. The streams of collagen and alginate are miscible and thus will flow parallel 
to each other as depicted in Figure 6-1 with minimal diffusion because of the 
short distance in which they are in contact with each other.  
 After passing through a singular focusing point at the junction with the oil 
phase, the collagen droplets will possess a shell of alginate around them. The 
thickness of the shell will be dependent on the ratio of the widths of the individual 
streams.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6-1: Design to provide the collagen-cell solution with an alginate shell. 
 The alginate shell will be discarded after the beads have been in the 
incubator for 1 day (this incubation period allows for complete collagen gellation) 
since the host immune responses towards alginate are unknown. Dissolving the 
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shell will be achieved by treating the beads with a dilute solution of Sodium 
Citrate that preferentially dissolves the Ca-Alginate. 
6.2.2 Three Dimensional Microscale Cell Culture 
 There is a tremendous amount of recent interest in culturing cells in PDMS 
based microchannel devices. This interest is due to the advantages offered by 
microfluidic systems previously detailed in earlier sections. Using a microfluidic 
chamber allows very few cells to be patterned in a microfluidic chamber and it is 
subsequently possible to analyze multiple variables on a single chip. These 
include single cell analyses and analyzing effect of toxins, growth factors, drugs 
and cytokines on the cultured cells.  
 Similar to macroscale cell culture systems, cells are still cultured in 
monolayers on PDMS or glass. A modification in the microchannel outlet design 
would allow us to entrap a select number of beads within the device and use it as 
a cell culture chamber. A schematic of such a culture chamber is shown in Figure 
6-2. 
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Figure 6-2: Device for 3-Dimensional culture at the microscale 
  
 The inlet channel architecture can be simply removed post encapsulation 
and replaced with a media chamber that will be cored into the PDMS. The beads 
will be allowed to settle in the micro-culture chamber under gravity and allowed to 
gel. The oil phase will be flushed out post gellation by operating a pump in the 
withdraw mode through the outlet port and replaced with media from the 
reservoir.  The small outlet channel and the ledge at the exit combined with the 
dynamics of the micro-scale flow will prevent the beads from clogging the outlet 
port.  
6.2.3 Transplant of Encapsulated Hepatic Progenitor Cells 
Hepatic progenitor cell death was associated with previous transplant 
experiments using alginate microspheres. This drop in viability was felt to be a 
function of the stresses exerted on the cells during the encapsulation procedure. 
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The benign nature of the collagen encapsulation system (due to the minimal 
stressors on the cells) ensures better long term cell viability. 
The HPCs inside the collagen microspheres will be transplanted by 
intrasplenic injection using a 27 gauge needle. GFP+ donor cells will be 
transplanted into wild type mice to test for cell survival in-vivo and host immune 
response to the transplanted beads. Collagen microspheres encapsulating HPCs 
will be transplanted into transgenic ApoE- mice to test for restoration of liver 
specific function. 
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